Corcept granted FDA nod for cancer therapy
Source: SeekingAlpha
2026-03-25 10:55:10 ET
More on Corcept Therapeutics
- Why Corcept's Ovarian Cancer 'Hail Mary' Might Actually Land
- Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript
- Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not
- Corcept rises after insider buy worth over $3M
- Mid-Cap healthcare stocks ranked by quant ratings after earnings season
Read the full article on Seeking Alpha
For further details see:
Corcept granted FDA nod for cancer therapy
Corcept Therapeutics Incorporated
NASDAQ: CORT
CORT Trading
-1.48% G/L:
$38.18 Last:
611,552 Volume:
$38.09 Open:
CORT Latest News
March 28, 2026 02:45:00 pm
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
March 25, 2026 04:56:46 pm
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday
CORT Stock Data
$4,351,636,537
83,309,068
0.22%
163
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
